This study is for people with metastatic castration-resistant prostate cancer (mCRPC), meaning prostate cancer that has spread and no longer responds to treatments that lower testosterone. It's a continuation study for those who have already participated in a ZEN003694 trial and are still benefiting from the treatment. You would continue to receive ZEN003694, possibly along with Enzalutamide. The main goal is to track any side effects (adverse events) you might experience while taking ZEN003694. To join, you must have completed a previous ZEN003694 study, be showing clinical benefit, and have a good performance status (ECOG 0 or 1).

Study design

This is an open-label, non-randomized study, meaning everyone receives the same treatment and you and your doctors will know what you are taking. It aims to enroll about 40 participants.

What's involved

You would continue to receive ZEN003694, potentially up to 120mg, and possibly Enzalutamide at 160mg. The study will monitor for side effects for up to 3 years.

Compensation

Not stated in the trial record.

Follow-up

Your treatment-related side effects will be monitored for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.